Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/sciences-de-la-vie/handbook-of-bioequivalence-testing-2nd-ed/niazi/descriptif_3173533
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=3173533

Handbook of Bioequivalence Testing (2nd Ed.) Drugs and the Pharmaceutical Sciences Series

Langue : Anglais

Auteur :

Couverture de l’ouvrage Handbook of Bioequivalence Testing

As the generic pharmaceutical industry continues to grow and thrive, so does the need to conduct adequate, efficient bioequivalence studies. In recent years, there have been significant changes to the statistical models for evaluating bioequivalence. In addition, advances in the analytical technology used to detect drug and metabolite levels have made bioequivalence testing more complex. The second edition of Handbook of Bioequivalence Testing has been completely updated to include the most current information available, including new findings in drug delivery and dosage form design and revised worldwide regulatory requirements. New topics include:

A historical perspective on generic pharmaceuticals

New guidelines governing submissions related to bioequivalency studies, along with therapeutic code classifications

Models of noninferiority

Biosimilarity of large molecule drugs

Bioequivalence of complementary and alternate medicines

Bioequivalence of biosimilar therapeutic proteins and monoclonal antibodies

New FDA guidelines for bioanalytical method validation

Outsourcing and monitoring of bioequivalence studies

The cost of generic drugs is rising much faster than in the past, partly because of the increased costs required for approval—including those for bioequivalence testing. There is a dire need to re-examine the science behind this type of testing to reduce the burden of development costs—allowing companies to develop generic drugs faster and at a lower expense. The final chapter explores the future of bioequivalence testing and proposes radical changes in the process of biowaivers. It suggests how the cost of demonstrating bioequivalence can be reduced through intensive analytical investigation and proposes that regulatory agencies reduce the need for bioequivalence studies in humans. Backed by science and updated with the latest research, this book is destined to spark continued debate on the efficacy of the current bioequivalence testing paradigm.

Historical Perspective on Generic Pharmaceuticals
Physicochemical Basis of Bioequivalence Testing
Drug Delivery Factors
Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling
Bioequivalence Testing Rationale and Principles
Bioequivalence Waivers
Statistical Evaluation of Bioequivalence Data
Regulatory Inspection Process
Fed Bioequivalence Studies
Topical Drugs
Bioequivalence of Nasal Products
Bioequivalence of Complementary and Alternate Medicines
Bioequivalence of Biosimilar Products
Bioequivalence Testing: The US Perspective
Bioequivalence Testing: European Perspective
Bioequivalence Testing: The ROW Perspective
Bioequivalence Testing Protocols
Bioequivalence Documentation
Good Laboratory Practices
Bioanalytical Method Validation
Good Clinical Practice
Computer and Software Validation
Outsourcing and Monitoring of Bioequivalence Studies
Epilogue: Future of Bioequivalence Testing
Appendix A: Glossary of Terms
Appendix B: Dissolution Testing Requirements for US FDA Submission
Bibliography
Index

Pharmaceutical and analytical scientists in generic pharmaceutical industries, regulatory agencies, statisticians, data analysts, and undergraduate and graduate students in pharmacy.

Date de parution :

17.8x25.4 cm

Disponible chez l'éditeur (délai d'approvisionnement : 13 jours).

Prix indicatif 173,96 €

Ajouter au panier
En continuant à naviguer, vous autorisez Lavoisier à déposer des cookies à des fins de mesure d'audience. Pour en savoir plus et paramétrer les cookies, rendez-vous sur la page Confidentialité & Sécurité.
FERMER